Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


Sage Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. ZULRESSO™ (brexanolone) injection is a rapidly acting GABA modulator now approved by the U.S. Food and Drug Administration as the first and only treatment specifically indicated for postpartum depression, pending DEA scheduling. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

April 18, 2019
Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019

April 3, 2019
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 19, 2019
Sage Therapeutics Announces FDA Approval of ZULRESSOâ„¢ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression

Read More News

Associated Team Members

Kevin Starr
Partner